1Harris AL. Angiogenesis as a new target for cancer control. EJC, 2003,1 : 1-7.
2Mooteri H, Rubin D, Leurgans S, et al. Tumor angiogenesis in primary and metastatic colorectal cancers. Dis Colon Rectum, 1996039 : 1073-1080.
3Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med, 1971,285: 1182-1186.
4Kaio E, Tanaka S, Kitadai Y, et al. Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology, 2003,64 : 61-73.
5Brem S. Angiogenesis and cancer control: From concept to therapeutic trial. Cancer Control, 1999,6 : 436-458.
6Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 1997,390 : 404-409.
7O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 1997,88 : 277-285.
8Shi W, Teschendorf C, Muzyezka N, et al. Adeno-associated virusmediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Therapy, 2002,9:513-521.
